Valbenazine for the treatment of tardive dyskinesia

Expert Review of Neurotherapeutics

Volumn 17, Issue 12, 2017, Pages 1135-1144

  Müller, Thomas ^a  

^a St Joseph Hospital Berlin Weissensee   (Germany)

Author keywords

tardive dyskinesia; Tetrabenazine; valbenazine; vesicular monoamine transporter 2

Indexed keywords

TETRABENAZINE; VALBENAZINE; ADRENERGIC RECEPTOR AFFECTING AGENT; VALINE;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; DECREASED APPETITE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; LONG QT SYNDROME; MAXIMUM PLASMA CONCENTRATION; MEDLINE; META ANALYSIS; MONOAMINE METABOLISM; NAUSEA; PHARMACODYNAMICS; RISK FACTOR; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; ANALOGS AND DERIVATIVES;

ADRENERGIC UPTAKE INHIBITORS; HUMANS; TARDIVE DYSKINESIA; TETRABENAZINE; VALINE;

EID: 85031420797     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1080/14737175.2017.1386556     Document Type: Article

References (51)

1. Fernandez HH, Friedman JH., Classification and treatment of tardive syndromes. Neurologist. 2003;9:16–27.
2. Müller T, Russ H., Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin Pharmacother. 2006;7:1715–1730.
3. Chen JJ, Ondo WG, Dashtipour K, et al. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487–1504.
4. Ehrenpreis ED, Deepak P, Sifuentes H, et al. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol. 2013;108:866–872.
5. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11:166–176.
6. Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatr. 2013;6:439–451.
7. Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry. 1991;148:1055–1059.
8. Kimiagar I, Dobronevsky E, Prokhorov T, et al. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol. 2012;259:660–664.
9. Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016;21:13–24.
10. Greenbaum L, Alkelai A, Zozulinsky P, et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J. 2012;12:513–520.
11. Tsai HT, Caroff SN, Miller DD, et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:336–340.
12. Zai CC, De L V, Hwang RW, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry. 2007;12:794–795.
13. Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res. 2013;47:1760–1765.
14. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76:779–787.
15. LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol. 2013;36:92–93.
16. Dorsey ER, Brocht AF, Nichols PE, et al. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis. 2013;2:509–515.
17. Dorsey R, Biglan K, Eberly S, et al. Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study. PLoS Curr. 2011;3:RRN1283.
18. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11:1509–1523.
19. Kenney C, Hunter C, Mejia N, et al. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29:259–264.
20. Harbeson SL, Morgan AJ, Liu JF, et al. Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther. 2017;362:359–367.
21. Howland RH. Deuterated drugs. J Psychosoc Nurs Ment Health Serv. 2015;53:13–16.
22. Coppen EM, Roos RA. Current pharmacological approaches to reduce chorea in Huntington’s disease. Drugs. 2017;77:29–46.
23. Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. Jama. 2016;316:40–50.
24. Frank S, Stamler D, Kayson E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74:977–982.
25. Geschwind MD, Paras N. Deutetrabenazine for treatment of chorea in Huntington disease. Jama. 2016;316:33–35.
26. Traynor K. Valbenazine approved for treatment of tardive dyskinesia. Am J Health Syst Pharm. 2017;74:628–629.
27. Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci. 2013;34:489–496.
28. Grigoriadis DE, Smith E, Hoare SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361:454–461.
29. FDA website. INGREZZA prescribing information. 2017.
30. Napadano J. Neuocrine biosciences; INC. Zacks Small Cap Res. 2014;1:15-22.
31. O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687.
32. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484.
33. Josisann RC, Kane JM,Liabng GS, et al. Safety and tolerability of valbenazine (nbi-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull. 2017;47:61–68.
34. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–2010.
35. Filip M, Frankowska M, Jastrzebska J, et al. Preclinical studies on comorbidity between depression and psychostimulant addiction. Pharmacol Rep. 2013;65:1529–1534.
36. Ferre S. Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders. Psychopharmacology (Berl). 2016;233:1963–1979.
37. Galvalisi M, Prieto JP, Martinez M, et al. Caffeine induces a stimulant effect and increases dopamine release in the nucleus accumbens shell through the pulmonary inhalation route of administration in rats. Neurotox Res. 2017;31:90–98.
38. Nall AH, Shakhmantsir I, Cichewicz K, et al. Caffeine promotes wakefulness via dopamine signaling in Drosophila. Sci Rep. 2016;6:20938.
39. Bordia T, McIntosh JM, Quik M. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. J Pharmacol Exp Ther. 2012;340:612–619.
40. Domino EF, Ni L, Domino JS, et al. Denicotinized versus average nicotine tobacco cigarette smoking differentially releases striatal dopamine. Nicotine Tob Res. 2013;15:11–21.
41. Sun N, Laviolette SR. Dopamine receptor blockade modulates the rewarding and aversive properties of nicotine via dissociable neuronal activity patterns in the nucleus accumbens. Neuropsychopharmacology. 2014;39:2799–2815.
42. Skor H, Smith EB, Loewen G, et al. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017; Epub.
43. Riederer P, Muller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol. 2017;13:233–240.
44. Shen V, Clarence-Smith K, Hunter C, et al. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3: pii: tre-03-191-4307-1. doi:10.7916/D8BK1B2D.
45. Davis MC, Miller BJ, Kalsi JK, et al. Efficient trial design–FDA approval of valbenazine for tardive dyskinesia. N Engl J Med. 2017;376:2503–2506.
46. Lidstone SC. Great expectations: the placebo effect in Parkinson’s disease. Handb Exp Pharmacol. 2014;225:139–147.
47. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22:179–186.
48. Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord. 2014;20:947–956.
49. Poulopoulos M, Hajjar M. Post-traumatic tics and tetrabenazine treatment: a blinded video assessment. BMJ Case Rep. 2013;2013: pii: bcr2013201676. doi:10.1136/bcr-2013-201676.
50. Paton DM. Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome. Drugs Today (Barc). 2017;53:89–102.
51. Reilmann R. Deutetrabenazine–not a revolution but welcome evolution for treating chorea in Huntington disease. JAMA Neurol. 2016;73:1404–1406.